Janssen’s proprietary PER.C6 human cell line technology provides a cost-effective manufacturing system for high-yield, large-scale production of vaccines and monoclonal antibodies. Dornan was commissioned to complete mechanical, electrical and instrumentation work at its pilot facility for this new technology at the company’s existing site in Leiden. Having to work within the constraints of a fully-operational site, Dornan undertook much of this work on night shifts.